CN104945395B - 二氢嘧啶类化合物及其在药物中的应用 - Google Patents
二氢嘧啶类化合物及其在药物中的应用 Download PDFInfo
- Publication number
- CN104945395B CN104945395B CN201510141969.5A CN201510141969A CN104945395B CN 104945395 B CN104945395 B CN 104945395B CN 201510141969 A CN201510141969 A CN 201510141969A CN 104945395 B CN104945395 B CN 104945395B
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- thiazol
- synthesis
- morpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Bc1cc(F)ccc1[C@@]1N=C(c2ncc[s]2)NC(CN2CC(CCC(O)=O)OCC2)=C1C(OC)=* Chemical compound Bc1cc(F)ccc1[C@@]1N=C(c2ncc[s]2)NC(CN2CC(CCC(O)=O)OCC2)=C1C(OC)=* 0.000 description 26
- YMUWWZRASYKWQY-VFNWGFHPSA-N CC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O YMUWWZRASYKWQY-VFNWGFHPSA-N 0.000 description 1
- ZDXVLPOPYFWHAP-QMMMGPOBSA-N CC(CC[C@@H]1NCCOC1)=O Chemical compound CC(CC[C@@H]1NCCOC1)=O ZDXVLPOPYFWHAP-QMMMGPOBSA-N 0.000 description 1
- NYDCUGHAYWYXML-VFYCCFAGSA-N CCOC(C1=C(CN(CCOC2)/C2=C/CC(O)=O)NC(c2ncc[s]2)=N[C@@H]1c(c(Br)c1)ccc1F)=[U] Chemical compound CCOC(C1=C(CN(CCOC2)/C2=C/CC(O)=O)NC(c2ncc[s]2)=N[C@@H]1c(c(Br)c1)ccc1F)=[U] NYDCUGHAYWYXML-VFYCCFAGSA-N 0.000 description 1
- DJFWONZOWWUNRA-PEJQNEDZSA-N CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=NC1[C@H](C)c(c(C)c1)ccc1[I]=C)=O Chemical compound CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=NC1[C@H](C)c(c(C)c1)ccc1[I]=C)=O DJFWONZOWWUNRA-PEJQNEDZSA-N 0.000 description 1
- KLOOZMZSXQVPOP-KUXBLMNESA-N CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(C1CCC1)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2CC(CC(C)(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(C1CCC1)c1)ccc1F)=O KLOOZMZSXQVPOP-KUXBLMNESA-N 0.000 description 1
- AWQQRHKGJGKHPZ-TUUUUVLKSA-N CCOC(C1=C(CN2C[C@@H](CCCC(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@@H](CCCC(C)C(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O AWQQRHKGJGKHPZ-TUUUUVLKSA-N 0.000 description 1
- IWJQEPHIFKEPTF-BTYIYWSLSA-N CCOC(C1=C(CN2C[C@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2C[C@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O IWJQEPHIFKEPTF-BTYIYWSLSA-N 0.000 description 1
- CZVDQFYWJLGGKP-BRNPAFAOSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)COCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O CZVDQFYWJLGGKP-BRNPAFAOSA-N 0.000 description 1
- DGHQAPJBSVUVGF-BRNPAFAOSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)CSCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)CSCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Br)=O DGHQAPJBSVUVGF-BRNPAFAOSA-N 0.000 description 1
- GZMVSOUMZTVQQX-FGKVNXAVSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(ccc(F)c1)c1Cl)=O GZMVSOUMZTVQQX-FGKVNXAVSA-N 0.000 description 1
- JRSOYUHCIKHPFU-XCQZSARTSA-N CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=C[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H](CC(C)C(O)=O)[C@@H](C)OCC2)NC(c2ncc[s]2)=C[C@H]1c(c(Cl)c1)ccc1F)=O JRSOYUHCIKHPFU-XCQZSARTSA-N 0.000 description 1
- JCMNLGGCPCDXEQ-FGCOXFRFSA-N CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O Chemical compound CCOC(C1=C(CN2[C@H](CCC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1Cl)=O JCMNLGGCPCDXEQ-FGCOXFRFSA-N 0.000 description 1
- UFIPRQDAKPUFRJ-HOQXQUDTSA-N CCOC(C1=C(CN2[C@H](CCC3OC3O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H](CCC3OC3O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O UFIPRQDAKPUFRJ-HOQXQUDTSA-N 0.000 description 1
- HLWIPUZHQKJFID-ZZZCEONXSA-N CCOC(C1=C(CN2[C@H]([C@H](C)CC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@]1(C)c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN2[C@H]([C@H](C)CC(O)=O)[C@@H](C(C)C)OCC2)NC(c2ncc[s]2)=N[C@]1(C)c(c(Br)c1)ccc1F)=O HLWIPUZHQKJFID-ZZZCEONXSA-N 0.000 description 1
- QMHPIVXBAMUETA-OSPHWJPCSA-N CCOC(CC1=C(CN2C[C@@H](CCC(CC(O)=O)(F)F)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=N Chemical compound CCOC(CC1=C(CN2C[C@@H](CCC(CC(O)=O)(F)F)OCC2)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=N QMHPIVXBAMUETA-OSPHWJPCSA-N 0.000 description 1
- MYXIBPRZMDKZRH-PJFKCVFWSA-N CCOCC(C1=C(CN2C[C@@H](CCC(C)=O)OCC2)NC(c2ncc[s]2)=NC1C/C=C\C(\Cl)=C/C(C)Cl)=O Chemical compound CCOCC(C1=C(CN2C[C@@H](CCC(C)=O)OCC2)NC(c2ncc[s]2)=NC1C/C=C\C(\Cl)=C/C(C)Cl)=O MYXIBPRZMDKZRH-PJFKCVFWSA-N 0.000 description 1
- QOBYCXCWVMTCSB-PEGVVKOVSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1C1C=CC(F)=CC1CCl)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1C1C=CC(F)=CC1CCl)=O QOBYCXCWVMTCSB-PEGVVKOVSA-N 0.000 description 1
- BWVKMHFWCULXRS-VLIAUNLRSA-N COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O Chemical compound COC(C1=C(CN2C[C@@H](CCC(O)=O)OCC2)NC(c2ncc[s]2)=N[C@H]1c1ccccc1Cl)=O BWVKMHFWCULXRS-VLIAUNLRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510141969.5A CN104945395B (zh) | 2014-03-28 | 2015-03-27 | 二氢嘧啶类化合物及其在药物中的应用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014101262020 | 2014-03-28 | ||
| CN201410126202 | 2014-03-28 | ||
| CN201410596489 | 2014-10-29 | ||
| CN2014105964893 | 2014-10-29 | ||
| CN201510141969.5A CN104945395B (zh) | 2014-03-28 | 2015-03-27 | 二氢嘧啶类化合物及其在药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104945395A CN104945395A (zh) | 2015-09-30 |
| CN104945395B true CN104945395B (zh) | 2018-01-23 |
Family
ID=54160517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510141969.5A Active CN104945395B (zh) | 2014-03-28 | 2015-03-27 | 二氢嘧啶类化合物及其在药物中的应用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9771358B2 (enExample) |
| EP (1) | EP3122747B1 (enExample) |
| JP (1) | JP2017512789A (enExample) |
| KR (1) | KR20160133563A (enExample) |
| CN (1) | CN104945395B (enExample) |
| AU (1) | AU2015236982B2 (enExample) |
| CA (1) | CA2938050A1 (enExample) |
| MX (1) | MX2016012573A (enExample) |
| MY (1) | MY196243A (enExample) |
| RU (1) | RU2682672C2 (enExample) |
| SG (1) | SG11201605896WA (enExample) |
| WO (1) | WO2015144093A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037918B1 (ru) | 2011-12-21 | 2021-06-07 | Новира Терапьютикс, Инк. | Противовирусные агенты против гепатита в |
| HK1208465A1 (en) | 2012-08-28 | 2016-03-04 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| DK2961732T3 (en) | 2013-02-28 | 2017-07-10 | Janssen Sciences Ireland Uc | SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B |
| WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| RS57999B1 (sr) | 2013-05-17 | 2019-01-31 | Janssen Sciences Ireland Uc | Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| ES2774749T3 (es) | 2013-07-25 | 2020-07-22 | Janssen Sciences Ireland Unlimited Co | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B |
| KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도 |
| ES2688600T3 (es) | 2013-11-27 | 2018-11-05 | Sunshine Lake Pharma Co., Ltd. | Procesos para preparar derivados de dihidropirimidina e intermedios de los mismos |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
| DK3102572T3 (en) | 2014-02-06 | 2019-02-04 | Janssen Sciences Ireland Uc | SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B |
| WO2016149581A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| HK1259410A1 (zh) | 2015-09-29 | 2019-11-29 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| BR112018067964B1 (pt) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc | Composto, composição farmacêutica que o compreende e uso do referido composto |
| EP3442524A2 (en) | 2016-04-15 | 2019-02-20 | Novira Therapeutics Inc. | Combinations and methods comprising a capsid assembly inhibitor |
| CN107400125B (zh) * | 2016-05-19 | 2020-02-11 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物的晶型、盐和复合物及其在药物中的应用 |
| MX2018015315A (es) | 2016-06-10 | 2019-04-25 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b. |
| CN107674072B (zh) * | 2016-08-01 | 2020-11-24 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物及其酸加成物的制备方法 |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| PL3508483T3 (pl) | 2016-11-18 | 2022-02-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Związek dihydropirymidynowy oraz sposób jego wytwarzania i jego zastosowanie |
| US11142527B2 (en) * | 2017-06-26 | 2021-10-12 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and uses thereof in medicine |
| WO2019001420A1 (en) | 2017-06-27 | 2019-01-03 | Janssen Pharmaceutica Nv | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS |
| IL272941B2 (en) | 2017-08-28 | 2023-03-01 | Enanta Pharm Inc | Antiviral agents for viral hepatitis b |
| CN111527087A (zh) | 2017-11-02 | 2020-08-11 | 艾库里斯有限及两合公司 | 具有抗乙型肝炎病毒(hbv)活性的新的高活性的吡唑并-哌啶取代的吲哚-2-甲酰胺 |
| GEP20227373B (en) | 2017-11-02 | 2022-04-25 | Aicuris Gmbh & Co Kg | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| EA202092171A1 (ru) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Схема дозирования модулятора сборки капсида |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN108329308B (zh) | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
| CN109021015B (zh) * | 2018-07-12 | 2019-12-03 | 山东大学 | 二氢嘧啶-磷酰胺类衍生物及其制备方法与应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| WO2020061435A1 (en) | 2018-09-21 | 2020-03-26 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| UY38435A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
| PY1991603A (es) | 2018-11-02 | 2020-09-17 | Aicuris Gmbh & Co Kg | Nueva 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole -2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| CA3118339A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) |
| UY38437A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv) |
| AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| KR102819704B1 (ko) | 2018-11-21 | 2025-06-11 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스제로서의 작용화된 헤테로사이클 |
| TW202035412A (zh) * | 2018-12-20 | 2020-10-01 | 比利時商健生藥品公司 | 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法 |
| MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| BR112021021580A2 (pt) | 2019-04-30 | 2022-01-04 | Aicuris Gmbh & Co Kg | Fenil e piridil ureias inovadoras ativas contra o vírus da hepatite b (hbv) |
| EP3962914A1 (en) | 2019-04-30 | 2022-03-09 | AiCuris GmbH & Co. KG | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
| JP2022533007A (ja) | 2019-04-30 | 2022-07-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のインドリジン－２－カルボキサミド |
| BR112021021652A2 (pt) | 2019-04-30 | 2021-12-21 | Aicuris Gmbh & Co Kg | Oxalil piperazinas inovadoras ativas contra o vírus da hepatite b (hbv) |
| BR112021021454A2 (pt) | 2019-05-06 | 2021-12-21 | Janssen Sciences Ireland Unlimited Co | Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| CA3140690A1 (en) * | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN110615797A (zh) * | 2019-10-11 | 2019-12-27 | 李丽丽 | 用于治疗乙型肝炎的化合物及其用途 |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CA3204318A1 (en) | 2020-12-17 | 2022-06-23 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides |
| EP4289842A4 (en) | 2021-02-05 | 2025-01-08 | Hepagene Therapeutics (HK) Limited | Phenyldihydropyrimidine compound and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101328171A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种溴苯基-取代的噻唑二氢嘧啶 |
| CN103626752A (zh) * | 2012-08-24 | 2014-03-12 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0202654A3 (en) | 1985-05-20 | 1987-12-16 | E.R. Squibb & Sons, Inc. | 5-carboxy-1,4-dihydropyrimidine derivatives |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013126A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101328170B (zh) | 2007-06-18 | 2011-09-14 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| WO2008154819A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| CN101328168B (zh) | 2007-06-18 | 2011-09-07 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| CN101575318B (zh) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| AU2013207205B2 (en) | 2012-01-06 | 2017-02-02 | Janssen Sciences Ireland Uc | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664897B (zh) | 2012-09-01 | 2018-04-03 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925B (zh) | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| JP6113285B2 (ja) | 2012-09-10 | 2017-04-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン |
| CN103664899B (zh) | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| EP2917184A4 (en) | 2012-11-09 | 2016-06-29 | Univ Indiana Res & Tech Corp | ALTERNATIVE USES FOR HBV ARRANGEMENT EFFECTORS |
| JP2016522271A (ja) | 2013-03-20 | 2016-07-28 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | 細胞中のｈｂｖコアのための診断染色剤である蛍光ｈａｐ |
| WO2014184328A1 (en) | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| JP6524081B2 (ja) | 2013-11-19 | 2019-06-05 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | ジヒドロピリミジン化合物及び医薬におけるその適用 |
| CN104650069B (zh) | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| CN104650070B (zh) | 2013-11-25 | 2018-09-14 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| ES2688600T3 (es) * | 2013-11-27 | 2018-11-05 | Sunshine Lake Pharma Co., Ltd. | Procesos para preparar derivados de dihidropirimidina e intermedios de los mismos |
| AU2015226206B2 (en) | 2014-03-07 | 2017-03-16 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
| NZ727601A (en) | 2014-05-30 | 2022-01-28 | Qilu Pharmaceutical Co Ltd | Dihydropyrimido fused ring derivative as hbv inhibitor |
-
2015
- 2015-03-27 MY MYPI2016702906A patent/MY196243A/en unknown
- 2015-03-27 AU AU2015236982A patent/AU2015236982B2/en active Active
- 2015-03-27 KR KR1020167029448A patent/KR20160133563A/ko not_active Withdrawn
- 2015-03-27 WO PCT/CN2015/075299 patent/WO2015144093A1/en not_active Ceased
- 2015-03-27 CN CN201510141969.5A patent/CN104945395B/zh active Active
- 2015-03-27 JP JP2016558407A patent/JP2017512789A/ja active Pending
- 2015-03-27 MX MX2016012573A patent/MX2016012573A/es unknown
- 2015-03-27 SG SG11201605896WA patent/SG11201605896WA/en unknown
- 2015-03-27 US US15/116,226 patent/US9771358B2/en active Active
- 2015-03-27 RU RU2016138735A patent/RU2682672C2/ru active
- 2015-03-27 EP EP15769748.3A patent/EP3122747B1/en active Active
- 2015-03-27 CA CA2938050A patent/CA2938050A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101328171A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种溴苯基-取代的噻唑二氢嘧啶 |
| CN103626752A (zh) * | 2012-08-24 | 2014-03-12 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| 以乙肝病毒核衣壳为靶标的二氢嘧啶类化合物及其作用机制研究进展.;杨秀岩等，;《中国药物化学杂志》;20131231;第23卷(第6期);第493-498页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| MY196243A (en) | 2023-03-24 |
| EP3122747A1 (en) | 2017-02-01 |
| JP2017512789A (ja) | 2017-05-25 |
| MX2016012573A (es) | 2018-02-19 |
| CN104945395A (zh) | 2015-09-30 |
| SG11201605896WA (en) | 2016-08-30 |
| US20160347746A1 (en) | 2016-12-01 |
| KR20160133563A (ko) | 2016-11-22 |
| AU2015236982A1 (en) | 2016-08-11 |
| RU2016138735A3 (enExample) | 2018-05-03 |
| AU2015236982B2 (en) | 2017-12-14 |
| EP3122747A4 (en) | 2017-11-15 |
| RU2682672C2 (ru) | 2019-03-20 |
| WO2015144093A1 (en) | 2015-10-01 |
| EP3122747B1 (en) | 2020-05-20 |
| US9771358B2 (en) | 2017-09-26 |
| CA2938050A1 (en) | 2015-10-01 |
| RU2016138735A (ru) | 2018-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104945395B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650068B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN109678859B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN104926808B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664899B (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650069A (zh) | 4-甲基二氢嘧啶类化合物及其在药物中的应用 | |
| CN109111451B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664925A (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650070B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| KR102496508B1 (ko) | 디하이드로피리미딘 화합물 및 이러한 화합물의 제조 방법 및 용도 | |
| CN111825676A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| WO2020221280A1 (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN110903284A (zh) | 稠合三环类化合物及其在药物中的应用 | |
| CN111303118B (zh) | 化合物及其在治疗乙型肝炎中的用途 | |
| WO2021143885A1 (zh) | 稠合四环类化合物及其在药物中的应用 | |
| HK40002930A (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| HK40002930B (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| HK1228400B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1228400A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1224286B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK1206027B (en) | 2,4,5,6-substituted 3,6-dihydropyrimidine derivatives as hepatitis b virus (hbv) polymerase inhibitors for the treatment of e.g. chronic hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Heteroaryl-substituted dihydropyrimidine compounds and application thereof in medicines Effective date of registration: 20200514 Granted publication date: 20180123 Pledgee: Zhongrong International Trust Co.,Ltd. Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd. Registration number: Y2020990000464 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220915 Granted publication date: 20180123 Pledgee: Zhongrong International Trust Co.,Ltd. Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd. Registration number: Y2020990000464 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan) Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| CP03 | Change of name, title or address |